Roche

- Read more about In India Roche introduces new treatments for metastatic breast cancer patients
Roche Pharma India recently introduce two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer.
- Read more about Roche acquires Lumora’s heat elution technology
Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical research and industrial markets, has sold its proprietary nucleic acid heat elution purification technology to Roche. Roche has signed a definitive asset purchase agreement with Lumora for products associated with its proprietary nucleic acid heat elution purification technology that is designed for use with clinical specimens.
- Read more about Roche's investigational immunotherapy atezolizumab met endpoint in specific type of lung cancer
Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.
- Read more about Amgen, Roche joined for study on cancer immunotherapy with talimogene laherparepvec & atezolizumab
Amgen join with Roche on a phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
- Read more about US FDA grant Roche's cobas KRAS mutation test for diagnostic use
The US Food and Drug Administration (FDA) has approved Roche's cobas KRAS mutation test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumour samples from metastatic colorectal cancer (mCRC) patients and aid clinicians in determining a therapeutic path for them.
3 July 2012

Work as Product Specialist- South, North (RMD) in Roche

At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity, and on seeing each other’s differences as an advantage. To innovate healthcare, Roche has ambitious plans to keep learning and growing – and is seeking people who have the same goals for themselves.
26 April 2010

Liraglutide Superior to Sitagliptin When Added to Metformin for Glycemic Control

The addition of a glucagonlike peptide-1 (GLP-1) agonist in patients with inadequate glycemic control when treated with metformin alone resulted in significantly larger reductions in HbA1c levels when compared with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, a new study has shown.